• Something wrong with this record ?

Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine

DS. Dhanjal, R. Singh, V. Sharma, E. Nepovimova, V. Adam, K. Kuca, C. Chopra

. 2024 ; 31 (13) : 1646-1690. [pub] -

Language English Country United Arab Emirates

Document type Journal Article, Review

Grant support
2217/2022-2023 Excellence project PrF UHK
00179906 Ministry of Health project MHCZ - DRO (UHHK)

The foundations of cell reprogramming were laid by Yamanaka and co-workers, who showed that somatic cells can be reprogrammed into pluripotent cells (induced pluripotency). Since this discovery, the field of regenerative medicine has seen advancements. For example, because they can differentiate into multiple cell types, pluripotent stem cells are considered vital components in regenerative medicine aimed at the functional restoration of damaged tissue. Despite years of research, both replacement and restoration of failed organs/ tissues have remained elusive scientific feats. However, with the inception of cell engineering and nuclear reprogramming, useful solutions have been identified to counter the need for compatible and sustainable organs. By combining the science underlying genetic engineering and nuclear reprogramming with regenerative medicine, scientists have engineered cells to make gene and stem cell therapies applicable and effective. These approaches have enabled the targeting of various pathways to reprogramme cells, i.e., make them behave in beneficial ways in a patient-specific manner. Technological advancements have clearly supported the concept and realization of regenerative medicine. Genetic engineering is used for tissue engineering and nuclear reprogramming and has led to advances in regenerative medicine. Targeted therapies and replacement of traumatized , damaged, or aged organs can be realized through genetic engineering. Furthermore, the success of these therapies has been validated through thousands of clinical trials. Scientists are currently evaluating induced tissue-specific stem cells (iTSCs), which may lead to tumour-free applications of pluripotency induction. In this review, we present state-of-the-art genetic engineering that has been used in regenerative medicine. We also focus on ways that genetic engineering and nuclear reprogramming have transformed regenerative medicine and have become unique therapeutic niches.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014608
003      
CZ-PrNML
005      
20240905133338.0
007      
ta
008      
240725s2024 ts f 000 0|eng||
009      
AR
024    7_
$a 10.2174/0929867330666230503144619 $2 doi
035    __
$a (PubMed)37138422
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ts
100    1_
$a Dhanjal, Daljeet Singh $u School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
245    10
$a Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine / $c DS. Dhanjal, R. Singh, V. Sharma, E. Nepovimova, V. Adam, K. Kuca, C. Chopra
520    9_
$a The foundations of cell reprogramming were laid by Yamanaka and co-workers, who showed that somatic cells can be reprogrammed into pluripotent cells (induced pluripotency). Since this discovery, the field of regenerative medicine has seen advancements. For example, because they can differentiate into multiple cell types, pluripotent stem cells are considered vital components in regenerative medicine aimed at the functional restoration of damaged tissue. Despite years of research, both replacement and restoration of failed organs/ tissues have remained elusive scientific feats. However, with the inception of cell engineering and nuclear reprogramming, useful solutions have been identified to counter the need for compatible and sustainable organs. By combining the science underlying genetic engineering and nuclear reprogramming with regenerative medicine, scientists have engineered cells to make gene and stem cell therapies applicable and effective. These approaches have enabled the targeting of various pathways to reprogramme cells, i.e., make them behave in beneficial ways in a patient-specific manner. Technological advancements have clearly supported the concept and realization of regenerative medicine. Genetic engineering is used for tissue engineering and nuclear reprogramming and has led to advances in regenerative medicine. Targeted therapies and replacement of traumatized , damaged, or aged organs can be realized through genetic engineering. Furthermore, the success of these therapies has been validated through thousands of clinical trials. Scientists are currently evaluating induced tissue-specific stem cells (iTSCs), which may lead to tumour-free applications of pluripotency induction. In this review, we present state-of-the-art genetic engineering that has been used in regenerative medicine. We also focus on ways that genetic engineering and nuclear reprogramming have transformed regenerative medicine and have become unique therapeutic niches.
650    12
$a regenerativní lékařství $7 D044968
650    _2
$a lidé $7 D006801
650    12
$a přeprogramování buněk $7 D065150
650    _2
$a zvířata $7 D000818
650    _2
$a vývojová biologie $7 D015509
650    _2
$a genetické inženýrství $7 D005818
650    _2
$a tkáňové inženýrství $7 D023822
650    _2
$a indukované pluripotentní kmenové buňky $x metabolismus $x cytologie $7 D057026
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Singh, Reena $u School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
700    1_
$a Sharma, Varun $u Head of Bioinformatic Division, NMC Genetics India Pvt. Ltd., Gurugram, India
700    1_
$a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, 50003, Czech Republic $1 https://orcid.org/000000030281246X $7 xx0224758
700    1_
$a Adam, Vojtech $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno, CZ 613 00, Czech Republic $u Central European Institute of Technology, Brno University of Technology, Purkynova 123, Brno, CZ-612 00, Czech Republic
700    1_
$a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, 50003, Czech Republic $u Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove, 50005, Czech Republic $1 https://orcid.org/0000000196641109 $7 xx0041831
700    1_
$a Chopra, Chirag $u School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India
773    0_
$w MED00001274 $t Current medicinal chemistry $x 1875-533X $g Roč. 31, č. 13 (2024), s. 1646-1690
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37138422 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133332 $b ABA008
999    __
$a ok $b bmc $g 2144027 $s 1226474
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 31 $c 13 $d 1646-1690 $e - $i 1875-533X $m Current medicinal chemistry $n Curr Med Chem $x MED00001274
GRA    __
$a 2217/2022-2023 $p Excellence project PrF UHK
GRA    __
$a 00179906 $p Ministry of Health project MHCZ - DRO (UHHK)
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...